192989-95-0

Basic information

• Product Name: 1-Butyne, 4-(methylsulfonyl)-
• CAS NO: 192989-95-0
• Molecular Formula: C5H8O2S
• Molecular Weight: 132.183
• Mol File: 192989-95-0.mol

Chemical Properties

• CAS DataBase Reference: 1-Butyne, 4-(methylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butyne, 4-(methylsulfonyl)-(192989-95-0)
• EPA Substance Registry System: 1-Butyne, 4-(methylsulfonyl)-(192989-95-0)

Safety Data

• Hazardous Substances Data: 192989-95-0(Hazardous Substances Data)

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, 1-Butyne, 4-(methylsulfonyl)has 5 carbon atoms, 8 hydrogen atoms, 2 oxygen atoms, and 1 sulfur atom.

Explanation

1-Butyne, 4-(methylsulfonyl)is derived from butyne, which is an alkyne compound. Alkynes are hydrocarbons with at least one carbon-carbon triple bond.

Explanation

The methylsulfonyl group is a functional group consisting of a sulfur atom bonded to a methyl group and an oxygen atom. In 1-Butyne, 4-(methylsulfonyl)-, this group is attached to the fourth carbon atom in the molecule.

Explanation

1-Butyne, 4-(methylsulfonyl)is commonly used in the field of organic synthesis and chemical research due to its reactivity and potential to form new compounds.

Explanation

This compound has the ability to react with other chemicals, making it a versatile building block for creating a wide range of new compounds.

Explanation

As a precursor, 1-Butyne, 4-(methylsulfonyl)is used in the production of various pharmaceuticals, agrochemicals, and other specialty chemicals.

Explanation

Due to its potential hazards, it is crucial to handle and store 1-Butyne, 4-(methylsulfonyl)with care to ensure safety and prevent accidents.

Derivative of Butyne

Alkyne compound

Methylsulfonyl Group

Attached to the fourth carbon atom

Usage

Organic synthesis and chemical research

Reactivity

Potential to react with other chemicals

Applications

Pharmaceutical, agrochemical, and specialty chemical production

Hazardous Material

Proper handling and storage required

Upstream product

• 72486-09-0 methanesulfonic acid but-3-ynyl ester 
• 512-56-1 trimethyl phosphite 
• 38771-21-0 4-bromobut-1-yne 
• 10574-94-4 1-Methylmercapto-butin-⁽³⁾ 
• 5188-07-8 sodium thiomethoxide 
• 124-63-0 methanesulfonyl chloride 
• 927-74-2 3-Butyn-1-ol 

Downstream Products

• 107301-61-1 N-benzyl-4-amino-1-butyne 
• 192989-94-9 1-(3-Butynyl)-4-hydroxy-4-((4-chloro)phenyl)piperidine 
• 192989-99-4 4-benzyl-1-(3-Butynyl)piperidine 
• 192989-23-4 4-(4-chlorobenzyl)-1-but-3-ynylpiperidine 
• 192989-53-0 4-benzyl-4-hydroxy-1-but-3-ynylpiperidine 
• 192989-98-3 1-mesyl-4-(3-methylphenyl)but-3-yne 
• 192989-96-1 1-mesyl-4-phenylbut-3-yne 
• 1039433-76-5 (1S)-3-((2S,3R)-2-(4-{4-(acetyloxy)-3-[(acetyloxy)methyl]-3-hydroxybut-1-yn-1-yl}phenyl)-1-{4-[4-(methylsulfonyl)but-1-yn-1-yl]phenyl}-4-oxoazetidin-3-yl)-1-(4-fluorophenyl)propyl acetate 

Relevant articles and documents

General sulfone construction: Via sulfur dioxide surrogate control

A highly efficient one-step synthesis of alkyl-alkyl and aryl-alkyl sulfones with a facile combination of halides, sulfur dioxide surrogates and phosphate esters is described. When thiourea dioxide was employed as a reductive sulfur dioxide surrogate, alkyl-alkyl sulfones were obtained under transition metal free conditions. Aryl-alkyl sulfones were obtained with an extremely low catalytic loading (0.2 mol%) via altering the mask of sulfur dioxide surrogates to sodium dithionite. A phosphate ester was employed as a stable and readily available alkyl source. Notably, this protocol has been applied to the late-stage modification of natural products and bioactive molecules.

ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS

One object of the instant invention is to provide novel cholesterol absorption inhibitors of Formula I or pharmaceutically acceptable salts thereof.

Anti-hypercholesterolemic biaryl azetidinone compounds

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is an alkyl, alkeny or alkynyl group mono- or poly-substituted with —OH, —COOH or a combination of —OH and —COOH, and R9 contains an alkyl, alkeny or alkynyl group substituted with a heterocyclic ring, amino or sulfonyl. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethly)-1-piperidinyl]-butyl]-alpha,alpha-dimethylbenzeneacetic acid

A process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α,α-dimethylbenzeneacetic acid (Fexofenadine) of formula 1

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headaches, glaucoma, CMV retinitis, chronic pain, opioid tolerance or withdrawals, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described. Also described are novel methods for preparing 4-substituted piperidine analogs and novel intermediates of the 4-substituted piperidine analogs.